<DOC>
	<DOCNO>NCT02623010</DOCNO>
	<brief_summary>The study include 30 elderly patient age 60-85 primary CNS DLBCL . Induction treatment include Rituximab high dose methotrexate protocol ( contain least methotrexate one chemotherapy agent ) . Patients MRI document response CR PR enter study protocol maintenance phase include continous treatment Ibrutinib 560 mg day relapse disease progression occurrence limit toxicity</brief_summary>
	<brief_title>Bruton 's Tyrosine Kinase Inhibitor Ibrutinib Maintenance Treatment Elderly Patients With Primary CNS Lymphoma</brief_title>
	<detailed_description>30 elderly patient age 60-85 primary CNS DLBCL achieve response CR PR enter study protocol maintenance phase . Induction treatment include Rituximab high dose methotrexate protocol ( contain least methotrexate one chemotherapy agent ) . Patients MRI document response CR PR enter study protocol maintenance phase . Maintenance : 28 day cycle Ibrutinib 560 mg orally daily relapse disease progression occurrence limit toxicity Evaluation response : Radiologic evaluation MRI perform every 3 month . Neurologic status evaluation every 2 month Neurocognitive evaluation every 6 month</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Newly diagnose PCNSL patient whose age &gt; 60 year achieve response ( CR/PR ) first line immunochemotherapy treatment Tissue diagnosis mandatory unless positive cerebrospinal fluid ( CSF ) cytology vitrectomy diagnostic evidence systemic disease No contraindication high dose methotrexate ( HDMTX ) ( adequate renal function ) KPS &gt; 40 % , ECOG &lt; 3 Hematology value must within follow limit : Absolute neutrophil count ( ANC ) ≥ 1000/µl independent growth factor support Platelets ≥100,000/µl ≥50,000/µl bone marrow involvement independent transfusion support either situation • Biochemical value within follow limit : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 x ULN unless bilirubin rise due Gilbert 's syndrome nonhepatic origin Serum creatinine ≤ 2 x ULN estimate Glomerular Filtration Rate ( Cockroft Gault≥ 40 mL/min Major surgery within 4 week randomization . History stroke intracranial hemorrhage within 6 month prior randomization . Requires anticoagulation warfarin equivalent vitamin K antagonist ( eg , phenprocoumon ) . Requires treatment strong CYP3A inhibitor . Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month Screening , Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification . Vaccinated live , attenuated vaccine within 4 week randomization . Known history human immunodeficiency virus ( HIV ) active Hepatitis C Virus active Hepatitis B Virus infection uncontrolled active systemic infection require intravenous ( IV ) antibiotic . Any lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism ibrutinib capsule , put study outcome undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Primary CNS lymphoma</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Elderly</keyword>
	<keyword>Maintenance</keyword>
</DOC>